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This longitudinal study of acute optic neuritis (ON) investigated whether plasma
biomarkers for axonal injury and inﬂammation could be related to loss and recovery
of visual function.
Eighteen patients with ON and 14 control patients were included into this prospec-
tive study. Plasma NfHSMI35 (a surrogate for axonal injury), NOx and citrulline (sur-
rogates for inﬂammation) were measured by ELISA.
Patients with ON had higher median plasma NfHSMI35 levels when compared
to controls (0.17 ng/mL versus 0.005 ng/mL, p<0.05) and higher NOx levels (49
M versus 35.5, p<0.001). Plasma NfHSMI35 levels correlated inversely with visual
acuity at presentation (R=-0.67, p=0.01). NfHSMI35 was higher in patients with poor
(0.25 ng/mL) when compared to those with good recovery of visual acuity (0.09
ng/mL, p<0.05). Seventy–ﬁve percent of patients with high NfHSMI35 and high NOx
levels experienced a poor recovery as opposed to only 20% with high NOx but
normal NfHSMI35 levels.
NfHSMI35 a surrogate marker for axonal damage is a prognostic indicator and
should be considered in the design of neuroprotective treatment strategies.
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2The “axonal death cascade” (1) has been associated to nitric oxide (NO)
mediated damage in vitro (2). The relation of axonal degeneration in vivo to
NO release is not known. Acute optic neuritis provides a useful model be-
cause of the deﬁned onset and the anatomically restricted area of neuronal
damage (3; 4). Increased levels of the NO metabolites nitrite (NO2 ) and
nitrate (NO3 ) were found in the cerebrospinal ﬂuid and serum of patients
with optic neuritis (5; 6). Axonal loss appears to be linked to the acquisition
of permanent deﬁcit (7; 2; 8; 9; 10; 11; 12). However the role of inﬂamma-
tion in demyelinating disease is less well deﬁned and there is accumulating
evidence that immune-mediated inﬂammation possesses neuroprotective
properties (1; 13).
This study aimed to investigate the relationship between loss and recovery
of optic nerve function with surrogate markers for inﬂammation (citrulline
and the NO metabolites NO2  and NO3  (14; 15; 2; 16)) and for axonal
injury (neuroﬁlaments (17)) in patients with acute optic neuritis.
1 Patients and Methods
Patients presenting with symptoms suggestive of acute unilateral optic neu-
ritis (n=18) and an age-matched healthy control group (n=14) were included
in this prospective study (Table 1). Inclusion criteria were: progressive loss
of vision over a few days, decreased visual acuity (Snellen chart), decreased
colour vision (Ishihara colour plates) and relative afferent pupillary defect
(3). Because visual acuity (VA) was in most cases severely affected the
visual ﬁelds (VF) were usually assessed by confrontation. As this is not a
quantitative method this precluded the use of perimetry in the quantitative
assessment. Exclusion criteria were: any other macula or retinal pathology,
contemporaneous symptoms suggestive demyelination elseswere or lack of
spontaneous recovery. The study was approved by the local ethics commit-
tee. Recovery of VA and colour vision was assessed at each visit and once
recovery plateaued no further follow-up was arranged. The last recorded VA
was taken as the ﬁnal outcome. Brain and optic nerve MR imaging was per-
formed using a 1.5 Tesla system (Siemens AG, Erlangen, Germany) and
consisted of an axial T1 and T2 weighted spin echo MR imaging (3; 5).
Plasma was taken at the ﬁrst visit and levels of the phosphorylated neu-
roﬁlament heavy chain (NfHSMI35 ), NOx and citrulline were measured as
described (17; 16; 14).
Data analysis was performed using SAS. Because of non-Gaussian data
distribution the median and interquartile range are shown. All correlations
were studied using Spearman rank correlation coefﬁcient. Differences be-
tween groups were compared using the two-sided Wilcoxon two-sample
3test. Signiﬁcances based on small numbers were checked on a categorical
level using the two–sided Fischer’s exact test. Trend analysis was using the
Mantel-Haenzel (M-H2) test. A 5 % level of signiﬁcance was used through-
out.
2 Results
The diagnosis of optic neuritis was conﬁrmed in all 18 patients during follow-
up. However in 4 patients the blood sample was taken over 4 weeks after
onset of symptoms. These patients were therefore excluded from analysis.
The remaining 14 patients presented with a median time from onset of 2
weeks (Table 1). At presentation 10/14 (71%) of the patients had a VA of
less then 0.33 (6/18, 20/60 Snellen equivalent). In total 13/14 (93%) of pa-
tients showed sustained improvement of their VA during follow-up. A minor
degree of optic atrophy was observed in 44% of patients whose VA recov-
ered to over 0.33 (6/18). Optic nerve atrophy was more severe in those 36%
of patients who did not recover their VA above 0.33.
Plasma levels of NfHSMI35 (Figure 1 A) and NO metabolites (NOx) (Figure
1 B) were signiﬁcantly higher in ON patients than in controls (p<0.001,
p<0.01, respectively). No such difference was found for citrulline (Table 1).
There was a negative correlation between NfHSMI35 and VA at the time of
ﬁrst presentation (R=-0.67, p=0.01, Figure 1 C). One outlier with NfHSMI35 levels
of 0.65 ng/mL was observed. This 48 old male patient presented with a right
ON, VA was reduced to hand movement (6/60, 20/200 Snellen equivalent),
colour vision to 0/17 and there was a right RAPD. This patient had suffered
from an episode of myelitis 2 years ago. In the absence of any clinical signs
of myelitis no spinal MRI was performed. After the removal of this patient
from the study the correlation between NfHSMI35 and VA remained signiﬁ-
cant (R=-0.60, p<0.05), but the slope of the linear regression decreased
from -0.22 to -0.145.
No correlation between VA and either NOx or citrulline was found at presen-
tation. There was no correlation for either NfHSMI35 , NOx or citrulline with
age, time from onset and there was no gender difference.
Plasma NfHSMI35 levels at presentation were signiﬁcantly higher (0.25 ng/mL)
in the 36% of the patients with poor recovery of visual function (0.33, 6/18,
20/60 Snellen equivalent) when compared to those whose VA recovered
to above 0.33 (0.09 ng/mL, p<0.05). Signiﬁcance remained comparing pro-
portions of patients with NfHSMI35 levels above cut–off (Figure 1 A, p=0.015,
two–sided Fisher’s exact test). There was no difference for the NOx levels
at presentation between those with good versus poor visual recovery at
4follow-up (54.2 versus 44.6 M, p=0.1).
The combined relationship of elevated NOx and NfHSMI35 levels with recov-
ery of visual function was investigated by comparing proportions of pa-
tients with high levels (elevated above the top value of the control group;
NfHSMI35 > 0.17 ng/mL, NOx > 43.8 M). There was a signiﬁcant trend for
increased proportion of patients experiencing a poor recovery (M-H2=4.6,
p<0.05) across the following categories: NfH normal and NOx normal (0/3,
0% poor recovery), NfH normal and NOx high (1/5, 20% poor recovery),
NfH high and NOx normal (1/2, 50% poor recovery), NfH high and NOx
high (3/4, 75% poor recovery).
MRI was available in 10 of 14 patients, 6/10 had an isolated ON lesion
(NfHSMI35 0.12 ng/mL, NOx 40.7 M) as opposed to 40% with disseminated
brain lesions (NfHSMI35 0.17 ng/mL, NOx 52.9 M). Although NfHSMI35 and
NOx seemed to be marginally higher in patients with disseminated brain
lesions this did not reach statistical signiﬁcance.
3 Discussion
This is the ﬁrst study to measure biomarkers for axonal injury (NfHSMI35 )
and inﬂammation (NOx, citrulline) in the plasma of patients with acute optic
neuritis. The main ﬁndings were that NfHSMI35 levels were higher in ON than
in control patients, were inversely correlated to visual acuity at presentation
and were of prognostic signiﬁcance. This suggests the presence of axonal
damage in the acute phase. The results are in line with clinical, MRI and
electrophysiological evidence for optic nerve ﬁbre loss following a single
episode of ON and insidiously in MS (18; 19; 20).
Recovery of the VA to  6/18 (20/60) was achieved by less patients (36%)
compared to VA  20/50 (88%) in the optic neuritis treatment trial (ONTT)
after 5 years follow–up (4). Bradley and Whitty (1967) found that recovery of
VA to  20/30 was achieved by 50% after 1 month and 75% after 6 months
(21). The result of the present study may relate to the small sample in this
study and the relatively short period of follow up (25–189 days).
Recovery of VA in MS related ON has been attributed to resolution of con-
duction block caused by acute inﬂammation (19; 20). NO mediated con-
duction block also seems to be the initial mechanism in in vitro studies
(2; 22; 23). The present and one other study (5) failed to show a signiﬁcant
relationship between serum NOx levels and outcome. Additionally NOx and
NfHSMI35 did not correlate with MRI parameters, but this could be due to the
small study population. The almost 30-40% higher values, if true, might in-
5dicate demyelinating activity elsewhere contributing to the worse outcome.
Citrulline was thought to be a second marker for NO mediated inﬂammation,
but it did not correlate with NOx and no difference between ON and control
patients could be shown. This ﬁnding is in keeping with one study com-
paring CSF and serum citrulline levels between patients with Lewy body
dementia and healthy controls (18). We agree with these authors that cit-
rulline is not a good surrogate for NO metabolism because it is a substrate
for enzymes other than iNOS.
In MS it appears that inﬂammatory markers were predominately related to
disease activity and the MRI lesion load but not outcome (5; 24). In addition
epidemiological data suggested that inﬂammation in MS only has a limited
effect on the course of neurodegeneration (25). In placebo–controlled trials
and clinical experience with ON anti-inﬂammatory treatment with steroids
does not inﬂuence outcome in the majority of cases (3). The destructive
and neuroprotective aspects of inﬂammation have stimulated a controver-
sial discussion (1; 13; 26; 25; 5; 27). It is therefore interesting that in this
small group 4/5 (80%) of patients with elevated NOx levels but normal
NfHSMI35 levels made a good recovery. This ﬁnding highlights the potential
for selection bias in treatment trials for neuroprotective drugs by inclusion
of those patients with evidence of inﬂammation only.
Taken together, these ﬁndings support the concept that sustained loss of
optic nerve function relates to axonal degeneration and that NO might at
least in part contribute to the “axonal death cascade” (1; 2; 8; 9; 7).
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8Table 1: Characteristics of patients expressed as me-
dians (interquartile range). MRI = magnetic resonance
imaging, na = not assessed, RAPD = relative afferent
pupillary deﬁcit, VFD = visual ﬁeld defect.
Feature Controls Acute optic neuritis Signiﬁcance
Age (years) 36 (30–43) 36 (35-46)
Male: Female 4:10 9:5 p<0.05
Eye N/A R 8 : L 6
RAPD N/A R 8 : L 5
Visual acuity 1.2 0.2 (0.05 – 0.67)
Colour vision 17/17 0/17 (0/17 – 7/17)
Disc appearance Normal 2 swollen, 12 normal
Time from onset N/A 14 days (8 – 26)
Follow–up N/A 171 days (25 – 189)
MRI N/A 10
Plasma NfHSMI35 (ng/mL) 0.005 (0.0 – 0.094) 0.17 (0.07 – 0.33) p<0.001
Plasma NOx (M) 36.2 (31.2 – 38.6) 48.1 (40.8 – 54.2) p<0.01




Figure 1. (A) Plasma NfHSMI35 (ng/mL) levels and (B) NOx (M) levels in con-
trols (CTRL) and patients with acute optic neuritis (ON). The median (50%), box
(25%-75%) and whisker (0%-100%) are shown next to the individual values (open
circle). (C) Plasma NfHSMI35 correlates with visual acuity (VA) at time of sampling
(R=-0.66, p=0.01).
10